Roth starts NovaBay at buy
September 16, 2011 by leonardzehr · Leave a Comment
Tweet Roth Capital Partners has initiated coverage of NovaBay Pharmaceuticals (AMEX:NBY) with a “buy” rating and 12-month price target of $3.50, saying several news events related to clinical trial progress and the potential for commercial revenues in the next 12 months are “anticipated to drive the shares higher.” The stock closed at 92 cents on [...]
